Biocure Technology's CEO is Simon Cheng, appointed in Sep 2023, has a tenure of 2.67 years. total yearly compensation is CA$15.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth CA$204.18. The average tenure of the management team and the board of directors is 7.7 years and 8.3 years respectively.
Key information
Simon Cheng
Chief executive officer
CA$15.0k
Total compensation
CEO salary percentage
100.00%
CEO tenure
2.7yrs
CEO ownership
0.03%
Management average tenure
7.7yrs
Board average tenure
8.3yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Simon Cheng's remuneration changed compared to Biocure Technology's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
n/a
n/a
-CA$103k
Sep 30 2025
n/a
n/a
-CA$284k
Jun 30 2025
n/a
n/a
-CA$246k
Mar 31 2025
n/a
n/a
-CA$245k
Dec 31 2024
CA$15k
CA$15k
-CA$262k
Sep 30 2024
n/a
n/a
-CA$4m
Jun 30 2024
n/a
n/a
-CA$4m
Mar 31 2024
n/a
n/a
-CA$1m
Dec 31 2023
CA$10k
CA$10k
-CA$1m
Compensation vs Market: Simon's total compensation ($USD11.01K) is below average for companies of similar size in the Canadian market ($USD151.38K).
Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.
CEO
Simon Cheng (44 yo)
2.7yrs
Tenure
CA$15,000
Compensation
Mr. Yee Sing Cheng, also known as Simon, is Independent Director of Rush Gold Corp. from February 3, 2025. He serves as CEO & Director at Biocure Technology Inc. since September 8, 2023. He has been Chief...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Yee Cheng
CEO & Director
2.7yrs
CA$15.00k
0.029% CA$ 204.2
Konstantin Lichtenwald
CFO, Corporate Secretary & Director
8.2yrs
CA$110.00k
9.39% CA$ 66.4k
Marco Nonni
Consultant
7.7yrs
CA$16.50k
no data
7.7yrs
Average Tenure
Experienced Management: CURE.X's management team is seasoned and experienced (7.7 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Yee Cheng
CEO & Director
2.7yrs
CA$15.00k
0.029% CA$ 204.2
Konstantin Lichtenwald
CFO, Corporate Secretary & Director
8.2yrs
CA$110.00k
9.39% CA$ 66.4k
Sang Kim
Independent Director
10.8yrs
CA$90.00k
9.86% CA$ 69.8k
Jae Shin
Member of Advisory Board
8.3yrs
no data
no data
Hyun Lee
Member of Advisory Board
8.3yrs
no data
no data
Heon Lee
Member of Advisory Board
8.3yrs
no data
no data
8.3yrs
Average Tenure
44yo
Average Age
Experienced Board: CURE.X's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/07 18:44
End of Day Share Price
2026/02/26 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biocure Technology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.